Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
September 15, 2015
Baltimore biopharm gets NIH grant
AgeneBio, a Baltimore-based biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.
